Long-Term Iron Chelation Therapy with Deferiprone in Patients with Thalassemia Major and Low Iron Load

被引：1
|
作者：
Daar, Shahina [1 ]
Al-Khabori, Murtadha K. [2 ]
Al Farsi, Khalil [3 ]
Al-Rawahi, Bader Abdulla [1 ]
Al-Riyami, Arwa Z. [1 ,4 ]
机构：
[1] Sultan Qaboos Univ Hosp, Muscat, Oman
[2] Sultan Qaboos Univ Hosp, Dept Haematol, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Dept Haematol, Coll Med & Hlth Sci, Muscat, Oman
[4] Sultan Qaboos Univ Hosp, Al Khoud, Oman
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3626.3626
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3626
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload
    S. Daar
    A. V. Pathare
    Annals of Hematology, 2006, 85 : 315 - 319
  • [42] Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
    Meloni, Antonella
    Pistoia, Laura
    Ricchi, Paolo
    Allo, Massimo
    Rosso, Rosamaria
    Cuccia, Liana
    Casini, Tommaso
    Cecinati, Valerio
    Serra, Marilena
    Rossi, Vincenza
    Righi, Riccardo
    Renne, Stefania
    Vallone, Antonino
    Positano, Vincenzo
    Cademartiri, Filippo
    BLOOD ADVANCES, 2023, 7 (10) : 2237 - 2240
  • [43] EVALUATION OF IRON CHELATION THERAPY IN β-THALASSEMIA MAJOR PATIENTS IN EAST DELTA OF EGYPT
    Hassan, T.
    Badr, M.
    Hesham, M.
    Badawy, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 701 - 701
  • [44] Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with β-Thalassemia Major
    Forni, Gian Luca
    Podesta, Marina
    Musso, Marco
    Piaggio, Giovanna
    Musallam, Khaled M.
    Balocco, Manuela
    Pozzi, Sarah
    Frassoni, Francesco
    BLOOD, 2012, 120 (21)
  • [45] Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
    Rombos, Y
    Tzanetea, R
    Konstantopoulos, K
    Simitzis, S
    Zervas, C
    Kyriaki, P
    Kavouklis, M
    Aessopos, A
    Sakellaropoulos, N
    Karagiorga, M
    Kalotychou, V
    Loukopoulos, D
    HAEMATOLOGICA, 2000, 85 (02) : 115 - 117
  • [46] The Zinc and Copper Levels in Thalassemia Major Patients, Receiving Iron Chelation Therapy
    Zekavat, Omid R.
    Bahmanjahromi, Ayda
    Haghpanah, Sezaneh
    Ebrahimi, Sara
    Cohan, Nader
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (03) : 178 - 181
  • [47] Long-term evaluation of the efficiency of iron chelation in thalassemia major with balance studies using hepatic iron concentration to determine body iron stores.
    Brittenham, GM
    Taylor, CM
    Angelucci, E
    Olivieri, NF
    BLOOD, 1998, 92 (10) : 38B - 38B
  • [48] BONE MINERAL DENSITY IMPROVEMENT IN PATIENTS WITH THALASSEMIA MAJOR ON LONG-TERM CHELATION THERAPY WITH DEFERASIROX
    Casale, M.
    Citarella, S.
    Amendola, G.
    Iolascon, G.
    Costantini, S.
    De Michele, E.
    Pugliese, U.
    Tartaglione, I.
    Gallicola, F.
    Cinque, P.
    Filosa, A.
    Perrotta, S.
    HAEMATOLOGICA, 2014, 99 : 442 - 443
  • [49] Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
    Cohen, AR
    Galanello, R
    Piga, A
    De Sanctis, V
    Tricta, F
    BLOOD, 2003, 102 (05) : 1583 - 1587
  • [50] Transfusional Iron Overload and Iron Chelation Therapy in Thalassemia Major and Sickle Cell Disease
    Marsella, Maria
    Borgna-Pignatti, Caterina
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (04) : 703 - +
12345